≥99% HPLCPre-filled pen

Semaglutide

Name: Semaglutide
Brand: Dripfy
Availability: InStock

What it is?

Semaglutide is a GLP-1 receptor agonist studied for mimicking endogenous incretin signalling involved in satiety, glucose regulation, and appetite control. It is widely positioned for structured protocols focused on metabolic optimisation and sustainable weight-management endpoints.

Dripfy Advantage

Receptor engagement: Selective activation of GLP-1 receptors, aligning with established satiety and glycaemic-control signalling.
Central satiety modulation: Associated with reduced appetite drive and improved satiety-related behavioural endpoints.
Glycaemic stability: Supports glucose regulation markers through incretin-mediated insulin response dynamics.
Protocol consistency: Often positioned for predictable, trackable outcomes in weight-management research designs.

Composition & Formulation

Class: GLP-1 receptor agonist peptide
Format: Ready-to-use pre-filled pen

€478

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

Semaglutide

GLP-1 receptor agonist · Pre-filled pen

A· Strong evidence

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1. By activating GLP-1 receptors it enhances glucose-dependent insulin release, slows gastric emptying and acts on central appetite pathways to increase satiety. These combined actions underlie its well-studied effects on glycaemic control and body weight.

Studied use areas

Type 2 diabetes glycaemic control
Weight management and reduction of excess body weight
Appetite and satiety regulation
Cardiovascular risk endpoints in eligible patients

Safety & status

Prescription-only medicine in the EU and UK (EMA/MHRA); it must be prescribed and supervised by a physician
Commonly associated with gastrointestinal effects such as nausea, vomiting and constipation, especially early in treatment
Not for use in pregnancy and requires screening of personal/family history of certain thyroid tumours and pancreatitis
Any dose and titration are individualised and determined by the treating physician

⚕ Clinical note: This is educational information, not medical advice. Semaglutide is a prescription-only medicine and any use must be initiated and monitored by a qualified physician, who assesses suitability, benefits and risks individually.

Evidence: Grade A — approved medicine supported by large randomised controlled trials · References: GLP-1 receptor agonist randomised controlled weight-management and cardiovascular outcome trials; EMA/MHRA product information for GLP-1 receptor agonists; Peer-reviewed endocrinology and obesity-medicine literature